Therapeutic Effect of Vasoactive Intestinal Peptide on Experimental Autoimmune Encephalomyelitis

摘要: Multiple sclerosis (MS) is a disabling inflammatory, autoimmune demyelinating disease of the central nervous system. Despite intensive investigation, mechanisms pathogenesis remain unclear, and curative therapies are unavailable for MS. The current study describes possible new strategy treatment MS, based on administration vasoactive intestinal peptide (VIP), well-known immunosuppressive neuropeptide. Treatment with VIP significantly reduced incidence severity experimental encephalomyelitis (EAE), in MS-related rodent model suppressed EAE neuropathology by reducing system inflammation, including regulation wide spectrum inflammatory mediators, selectively blocking encephalitogenic T-cell reactivity. Importantly, was therapeutically effective established prevented recurrence disease. Consequently, represents novel multistep therapeutic approach future human